- Home
- PCVX vs GNTX Comparison
PCVX vs GNTX Comparison
Compare PCVX & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | GNTX |
|---|---|---|
| Founded | 2013 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCVX | GNTX |
|---|---|---|
| Price | $47.24 | $23.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $101.67 | $29.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.9M |
| Earning Date | 11-04-2025 | 01-30-2026 |
| Dividend Yield | N/A | ★ 2.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $2,431,504,922.00 |
| Revenue This Year | N/A | $11.92 |
| Revenue Next Year | N/A | $4.98 |
| P/E Ratio | ★ N/A | $13.82 |
| Revenue Growth | N/A | ★ 3.00 |
| 52 Week Low | $27.66 | $20.28 |
| 52 Week High | $93.77 | $29.52 |
Technical Indicators
Market Signals| Indicator | PCVX | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 49.55 |
| Support Level | $42.40 | $23.26 |
| Resistance Level | $48.65 | $24.09 |
| Average True Range (ATR) | 1.61 | 0.40 |
| MACD | 0.22 | 0.04 |
| Stochastic Oscillator | 77.06 | 36.47 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.